Infection with human T-cell leukemia virus type 1 (HTLV-1) is associated with adult T-cell leukemia (ATL) and tropical spastic paraparesis. Type I interferons (IFNs) are key effectors of the innate antiviral response, and IFN-␣ combined with the nucleoside reverse transcriptase inhibitor zidovudine is considered the standard first-line therapy for ATL. HTLV-1 oncoprotein Tax is known to suppress innate IFN production and response but the underlying mechanisms remain to be fully established. In this study, we report on the suppression of type I IFN production by HTLV-1 Tax
Five to 20 million people worldwide are infected with human T-cell leukemia virus type 1 (HTLV-1), among them about 3% might develop adult T-cell leukemia (ATL), and another 1% could suffer from tropical spastic paraparesis. Both diseases are poorly treatable (1, 2). A combination of alpha interferon (IFN-␣) and zidovudine has emerged as the standard first-line therapy for ATL (3, 4). Whereas zidovudine is a nucleoside analog that inhibits reverse transcriptase, IFN-␣ is an antiviral cytokine that serves as a key effector in innate immunity (5). Both IFN-␣ and zidovudine are required in this modality, but how they cooperate to achieve optimal therapeutic effect is not understood. To shed light on this, it will be of importance to elucidate how HTLV-1 perturbs type I IFN production and signaling.Recognition of pathogen-associated molecular patterns by pattern recognition receptors of the host cell triggers innate immune response, including the production of type I IFNs (6, 7). For example, upon recognition of viral nucleic acids, Toll-like and RIG-I-like receptors, as well as other sensors, generate an activation signal that is transmitted through adaptor proteins such as MAVS and STING, resulting in TBK1-dependent phosphorylation of IRF3 and IRF7 transcription factors which translocate into the nucleus to activate IFN promoters (8,9). Increased expression of type I IFNs ultimately leads to the activation of JAK-STAT signaling and the consequent induction of IFN-stimulated genes (ISGs), including those coding for some proinflammatory cytokines (10). Exactly how HTLV-1 infection is sensed by the host cell is poorly understood. The involvement of cytoplasmic RNA sensor RIG-I in the sensing of another retrovirus human immunodeficiency virus type 1 (HIV-1) has been suggested (11). Because optimal function of RIG-I requires PACT, a cellular double-